These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 9812219

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
    Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L.
    Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Assessment and management of scleroderma lung disease.
    Bolster MB, Silver RM.
    Curr Opin Rheumatol; 1999 Nov; 11(6):508-13. PubMed ID: 10551676
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Systemic sclerosis (scleroderma). Clinical management of its major complications.
    Legerton CW, Smith EA, Silver RM.
    Rheum Dis Clin North Am; 1995 Feb; 21(1):203-16. PubMed ID: 7732169
    [Abstract] [Full Text] [Related]

  • 8. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [Abstract] [Full Text] [Related]

  • 9. [Pulmonary involvement in progressive systemic sclerosis].
    Grisanti M, Vicencio M.
    Rev Med Chil; 1986 Oct; 114(10):1002-5. PubMed ID: 3575934
    [No Abstract] [Full Text] [Related]

  • 10. Scleroderma lung disease: "if you don't know where you are going, any road will take you there".
    Strange C, Seibold JR.
    Am J Respir Crit Care Med; 2008 Jun 01; 177(11):1178-9. PubMed ID: 18487619
    [No Abstract] [Full Text] [Related]

  • 11. [Cardiac and pulmonary involvement in scleroderma].
    Launay D, Hachulla E.
    Rev Prat; 2002 Nov 01; 52(17):1901-7. PubMed ID: 12532867
    [Abstract] [Full Text] [Related]

  • 12. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
    Mangat P, Conron M, Gabbay E, Proudman SM, Pulmonary Interstitial Vascular Organisational Taskforce (PIVOT).
    Intern Med J; 2010 Jul 01; 40(7):494-502. PubMed ID: 19460060
    [Abstract] [Full Text] [Related]

  • 13. Treatment Considerations of Lung Involvement in Rheumatologic Disease.
    Robles-Perez A, Molina-Molina M.
    Respiration; 2015 Jul 01; 90(4):265-74. PubMed ID: 26461464
    [Abstract] [Full Text] [Related]

  • 14. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
    Casale R, Generini S, Luppi F, Pignone A, Matucci-Cerinic M.
    Arthritis Rheum; 2004 Aug 15; 51(4):665-9. PubMed ID: 15334442
    [No Abstract] [Full Text] [Related]

  • 15. Pulmonary complications: one of the most challenging complications of systemic sclerosis.
    Wells AU, Steen V, Valentini G.
    Rheumatology (Oxford); 2009 Jun 15; 48 Suppl 3():iii40-4. PubMed ID: 19487223
    [Abstract] [Full Text] [Related]

  • 16. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
    Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, Cobankara V, Pay S, Calguneri M.
    Arthritis Rheum; 2003 Aug 15; 48(8):2256-61. PubMed ID: 12905480
    [Abstract] [Full Text] [Related]

  • 17. Scleroderma lung: pathogenesis, evaluation, and current therapy.
    Co HT, Block JA, Sequeira W.
    Am J Ther; 2000 Sep 15; 7(5):321-4. PubMed ID: 11317180
    [Abstract] [Full Text] [Related]

  • 18. Targeted therapy for systemic sclerosis.
    Steen V.
    Autoimmun Rev; 2006 Feb 15; 5(2):122-4. PubMed ID: 16431341
    [Abstract] [Full Text] [Related]

  • 19. The spectrum of scleroderma lung disease.
    Highland KB, Garin MC, Brown KK.
    Semin Respir Crit Care Med; 2007 Aug 15; 28(4):418-29. PubMed ID: 17764059
    [Abstract] [Full Text] [Related]

  • 20. Pulmonary involvement in systemic sclerosis due to therapy and as a complication.
    Chiappini F, Zoli A, Maugeri L.
    Monaldi Arch Chest Dis; 2005 Jun 15; 63(2):111-3. PubMed ID: 16128227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.